SCHEMBL12376737

SCHEMBL12376737

CC(=O)c1cccc(S(=O)(=O)NC(C)C)c1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 1/20 0.62
ALDH1A1 P00352 9/20 0.60
LMNA P02545 2/20 0.60
KMT2A Q03164 2/20 0.59
POLB P06746 1/20 0.58
SMN1; SMN2 Q16637 5/20 0.56
HSD17B10 Q99714 1/20 0.51
HDAC8 Q9BY41 2/20 0.50
HDAC6 Q9UBN7 2/20 0.50
ACLY P53396 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
MAPT P10636 2/20 0.48
HPGD P15428 1/20 0.48
CYP2C19 P33261 1/20 0.47
PTPN1 P18031 1/20 0.46
PTPN6 P29350 1/20 0.46
PTPN11 Q06124 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13543487 0.89 CA1 (0.62) HTR2BKMT2AHDAC8HDAC6CA1
SCHEMBL3649154 0.86 PTPN11 (0.57) HTR2BALDH1A1LMNAKMT2APOLB
SCHEMBL14507694 0.84 HTR2B (0.63) HTR2BALDH1A1LMNAKMT2APOLB
SCHEMBL12215906 0.84 POLB (0.58) ALDH1A1LMNAKMT2APOLBHDAC8
SCHEMBL13543277 0.83 HTR2B (0.55) HTR2BALDH1A1LMNAKMT2APOLB
SCHEMBL14612820 0.83 ALDH1A1 (0.67) ALDH1A1LMNAKMT2APOLBSMN1; SMN2
SCHEMBL4057326 0.81 ALDH1A1 (0.65) ALDH1A1LMNAKMT2APOLBSMN1; SMN2
SCHEMBL13701789 0.81 HTR2B (0.59) HTR2BALDH1A1LMNAKMT2AHDAC8
SCHEMBL13702296 0.81 SMN1; SMN2 (0.60) HTR2BALDH1A1KMT2APOLBSMN1; SMN2
SCHEMBL4731616 0.81 ALDH1A1 (0.50) HTR2BALDH1A1LMNAKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003662-B2 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. (US) 2011-08-23 US disclosed
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2010-10-07 US disclosed
US-7723330-B2 Heterobicyclic pyrazole compounds and methods of use ARRAY BIOPHARMA INC. (US) 2010-05-25 US disclosed
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use GENENTECH, INC. 2007-10-11 US disclosed
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ERBB2, LCK, SRC HTR2B 1176/4885ALDH1A1 1635/4885LMNA 4174/4885
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ROR1, CYP11B1, CYP11B2 HTR2B 297/4885ALDH1A1 1929/4885LMNA 1962/4885
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use ROR1, CYP11B1, CYP11B2 HTR2B 297/4885ALDH1A1 1929/4885LMNA 1962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.